Advances in magnetic resonance imaging and positron emission tomography imaging for grading and molecular characterization of glioma

Seminars in Radiation Oncology

Volumn 25, Issue 3, 2015, Pages 164-171

  Chung, Caroline ^a   Metser, Ur ^b,c   Ménard, Cynthia ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 FLUOROETHYL) LEVO TYROSINE F 18; FLUORINE 18; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHIONINE C 11; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; MULTIPARAMETRIC IMAGING; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BRAIN; BRAIN TUMOR; PATHOLOGY; SCINTISCANNING;

BRAIN; BRAIN NEOPLASMS; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84943147944     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2015.02.002     Document Type: Review

References (61)

1. Fellah S, Caudal D, De Paula AM, et al: Multimodal MR imaging (diffusion, perfusion, and spectroscopy): Is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? Am J Neuroradiol 34(7):1326-1333, 2013
2. Lee EJ, Lee SK, Agid R, et al: Preoperative grading of presumptive lowgrade astrocytomas on MR imaging: Diagnostic value of minimum apparent diffusion coefficient. Am J Neuroradiol 29(10):1872-1877, 2008
3. Law M, Yang S, Wang H, et al: Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 24 (10):1989-1998, 2003
4. Jenkinson MD, du Plessis DG, Smith TS, et al: Histological growth patterns and genotype in oligodendroglial tumours: Correlation with MRI features. Brain 129(Pt 7):1884-1891, 2006
5. Scott JN, Brasher PM, Sevick RJ, et al: How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59 (6):947-949, 2002
6. Guo J, Yao C, Chen H, et al: The relationship between Cho/NAA and glioma metabolism: Implementation for margin delineation of cerebral gliomas. Acta Neurochir (Wien) 154(8):1361-1370, 2012. [discussion 1370]
7. Faehndrich J, Weidauer S, Pilatus U, et al: Neuroradiological viewpoint on the diagnostics of space-occupying brain lesions. Clin Neuroradiol 21 (3):123-139, 2011
8. Haegler K, Wiesmann M, Bohm C, et al: New similarity search based glioma grading. Neuroradiology 54(8):829-837, 2012
9. Cha S: Update on brain tumor imaging: From anatomy to physiology. Am J Neuroradiol 27(3):475-487, 2006
10. Hilario A, Ramos A, Perez-Nunez A, et al: The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. Am J Neuroradiol 33(4):701-707, 2012
11. Maier SE, Sun Y, Mulkern RV: Diffusion imaging of brain tumors. NMR Biomed 23(7):849-864, 2010
12. Yamasaki F, Kurisu K, Satoh K, et al: Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 235(3):985-991, 2005
13. Holodny AI, Makeyev S, Beattie BJ, et al: Apparent diffusion coefficient of glial neoplasms: Correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging. Am J Neuroradiol 31(6):1042-1048, 2010
14. Higano S, Yun X, Kumabe T, et al: Malignant astrocytic tumors: Clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 241(3):839-846, 2006
15. Higano S, Yun X, Kumabe T, et al: Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard-or high-b-value diffusion-weighted MR imaging-correlation with tumor grade. Radiology 261(3):882-890, 2011
16. Murakami R, Hirai T, Sugahara T, et al: Grading astrocytic tumors by using apparent diffusion coefficient parameters: Superiority of a oneversus two-parameter pilot method. Radiology 251(3):838-845, 2009
17. Zonari P, Baraldi P, Crisi G: Multimodal MRI in the characterization of glial neoplasms: The combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging. Neuroradiology 49 (10):795-803, 2007
18. Catalaa I, Henry R, Dillon WP, et al: Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. NMR Biomed 19(4):463-475, 2006
19. Ellingson BM, Malkin MG, Rand SD, et al: Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31(3):538-548, 2010
20. Smitha KA, Gupta AK, Jayasree RS: Total magnitude of diffusion tensor imaging as an effective tool for the differentiation of glioma. Eur J Radiol 82(5):857-861, 2013
21. Ma L, Song ZJ: Differentiation between low-grade and high-grade glioma using combined diffusion tensor imaging metrics. Clin Neurol Neurosurg 115(12):2489-2495, 2013
22. Thompson G, Mills SJ, Stivaros SM, et al: Imaging of brain tumors: Perfusion/permeability. Neuroimaging Clin N Am 20(3):337-353, 2010
23. Cha S, Yang L, Johnson G, et al: Comparison of microvascular permeability measurements, K(trans), determined with conventional steadystate T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. Am J Neuroradiol 27(2):409-417, 2006
24. Choi HS, Kim AH, Ahn SS, et al: Glioma grading capability: Comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI. Korean J Radiol 14(3):487-492, 2013
25. Cha S, Knopp EA, Johnson G, et al: Dynamic contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. Am J Neuroradiol 21(5):881-890, 2000
26. Cha S, Knopp EA, Johnson G, et al: Glial neoplasms: Dynamic contrastenhanced T2-weighted MR imaging. Radiology 211(3):791-798, 1999
27. Aronen HJ, Gazit IE, Louis DN, et al: Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings. Radiology 191(1):41-51, 1994
28. Sugahara T, Korogi Y, Kochi M, et al: Correlation of MR imagingdetermined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. Am J Roentgenol 171 (6):1479-1486, 1998
29. Morita N, Wang S, Chawla S, et al: Dynamic susceptibility contrast perfusion weighted imaging in grading of nonenhancing astrocytomas. J Magn Reson Imaging 32(4):803-808, 2010
30. Lev MH, Ozsunar Y, Henson JW, et al: Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: Confounding effect of elevated rCBV of oligodendrogliomas [corrected]. Am J Neuroradiol 25 (2):214-221, 2004
31. Cebeci H, Aydin O, Ozturk-Isik E, et al: Assesment of perfusion in glial tumors with arterial spin labeling; comparison with dynamic susceptibility contrast method. Eur J Radiol 83(10):1914-1919, 2014
32. Noguchi T, Yoshiura T, Hiwatashi A, et al: Perfusion imaging of brain tumors using arterial spin-labeling: Correlation with histopathologic vascular density. Am J Neuroradiol 29(4):688-693, 2008
33. Weber MA, Henze M, Tuttenberg J, et al: Biopsy targeting gliomas: Do functional imaging techniques identify similar target areas? Invest Radiol 45(12):755-768, 2010
34. Di Costanzo A, Scarabino T, Trojsi F, et al: Proton MR spectroscopy of cerebral gliomas at 3 T: Spatial heterogeneity, and tumour grade and extent. Eur Radiol 18(8):1727-1735, 2008
35. Chen W, Silverman DH: Advances in evaluation of primary brain tumors. Semin Nucl Med 38(4):240-250, 2008
36. Mertens K, Acou M, Van Hauwe J, et al: Validation of 18 F-FDG PET at conventional and delayed intervals for the discrimination of high-grade from low-grade gliomas: A stereotactic PET and MRI study. Clin Nucl Med 38(7):495-500, 2013
37. Arbizu J, Tejada S, Marti-Climent JM, et al: Quantitative volumetric analysis of gliomas with sequential MRI and (1)(1)C-methionine PET assessment: Patterns of integration in therapy planning. Eur J Nucl Med Mol Imaging 39(5):771-781, 2012
38. 18F-FET PET for grading of recurrent gliomas: Is evaluation of uptake kinetics superior to standard methods? J Nucl Med 47(3):393-403, 2006
39. Fueger BJ, Czernin J, Cloughesy T, et al: Correlation of 6-18F-fluoro-Ldopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 51(10):1532-1538, 2010
40. 18F]-fluoro-L-dopa PET: What are we really measuring with minimum ADC? Am J Neuroradiol 34(4):758-764, 2013
41. Tripathi M, Sharma R, D'Souza M, et al: Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 34(12):878-883, 2009
42. 18F-FDOPA kinetics in brain tumors. J Nucl Med 48(10):1651-1661, 2007
43. Mills SJ, Soh C, Rose CJ, et al: Candidate biomarkers of extravascular extracellular space: A direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging-derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme. Am J Neuroradiol 31(3):549-553, 2010
44. Megyesi JF, Kachur E, Lee DH, et al: Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10(13):4303-4306, 2004
45. Chawla S, Krejza J, Vossough A, et al: Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusionweighted imaging and proton MR spectroscopy. Am J Neuroradiol 34 (8):1542-1549, 2013
46. Kapoor GS, Gocke TA, Chawla S, et al: Magnetic resonance perfusionweighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 92(3):373-386, 2009
47. Jenkinson MD, Smith TS, Joyce K, et al: MRS of oligodendroglial tumors: Correlation with histopathology and genetic subtypes. Neurology 64 (12):2085-2089, 2005
48. Choi C, Ganji SK, DeBerardinis RJ, et al: 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18(4):624-629, 2012
49. Pope WB, Prins RM, Albert Thomas M, et al: Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 107(1):197-205, 2012
50. Roder C, Bender B, Ritz R, et al: Intraoperative visualization of residual tumor: The role of perfusion-weighted imaging in a high-field intraoperative magnetic resonance scanner. Neurosurgery 72(2 Suppl Operative):P.ons151-158, 2013. [discussion ons158]
51. Castellano A, Bello L, Michelozzi C, et al: Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery. Neuro Oncol 14(2):192-202, 2012
52. Chang EF, Clark A, Smith JS, et al: Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: Improvement of longterm survival. Clinical article. J Neurosurg 114(3):566-573, 2011
53. Pirotte B, Goldman S, Dewitte O, et al: Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: A report of 103 consecutive procedures. J Neurosurg 104 (2):238-253, 2006
54. Roessler K, Gatterbauer B, Becherer A, et al: Surgical target selection in cerebral glioma surgery: Linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg 50(5):273-280, 2007
55. Pirotte BJ, Levivier M, Goldman S, et al: Positron emission tomographyguided volumetric resection of supratentorial high-grade gliomas: A survival analysis in 66 consecutive patients. Neurosurgery 64 (3):471-481, 2009. [discussion 481]
56. Kracht LW, Miletic H, Busch S, et al: Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: Local comparison with stereotactic histopathology. Clin Cancer Res 10(21):7163-7170, 2004
57. Astner ST, Dobrei-Ciuchendea M, Essler M, et al: Effect of 11Cmethionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys 72(4):1161-1167, 2008
58. Matsuo M, Miwa K, Tanaka O, et al: Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. Int J Radiat Oncol Biol Phys 82(1):83-89, 2012
59. 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: Results of a prospective pilot study. Neuro Oncol 15(8):1058-1067, 2013
60. Rieken S, Habermehl D, Giesel FL, et al: Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiother Oncol 109(3):487-492, 2013
61. 11C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for brain gliomas. Nucl Med Biol 39(3):437-442, 2012